Published in J Clin Microbiol on November 21, 2007
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol (2011) 1.48
Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat (2008) 1.21
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health (2010) 1.18
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol (2011) 1.18
Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics (2009) 1.07
Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index. J Infect Dis (2010) 1.03
Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One (2014) 0.99
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med (2014) 0.96
Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012. Emerg Infect Dis (2015) 0.94
Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One (2015) 0.87
Estimating acute viral hepatitis infections from nationally reported cases. Am J Public Health (2014) 0.87
Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. J Virol (2015) 0.86
Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection. J Virol (2015) 0.86
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study. J Infect Dis (2015) 0.85
Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. J Clin Virol (2014) 0.84
High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One (2013) 0.83
More rare birds, and the occasional swan. Gastroenterology (2009) 0.83
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One (2011) 0.83
Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat (2015) 0.82
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol (2014) 0.82
The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One (2015) 0.80
Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department. Clin Infect Dis (2016) 0.78
Per-event probability of hepatitis C infection during sharing of injecting equipment. PLoS One (2014) 0.78
Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report. J Assoc Nurses AIDS Care (2011) 0.76
Traceability, reproducibility and clinical evaluation of Sansure Realtime HCV RNA assay. BMC Infect Dis (2016) 0.75
Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. J Infect Dis (2016) 0.75
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat (2015) 0.75
Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. Clin Infect Dis (2016) 0.75
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis (2000) 6.05
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med (2004) 5.78
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol (2002) 4.20
Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol (2004) 4.12
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol (2003) 3.29
Tutorial in biostatistics methods for interval-censored data. Stat Med (1998) 3.29
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology (2006) 2.96
Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS (2005) 2.91
Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ (1998) 2.64
Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology (2001) 2.54
Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology (2004) 2.52
Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol (2004) 2.19
Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health (2001) 2.02
High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS (1995) 1.93
Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr (2000) 1.87
Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol (2003) 1.82
Acute hepatitis C. Hepatology (2001) 1.82
Dynamics of viremia in early hepatitis C virus infection. Transfusion (2005) 1.72
Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol (2002) 1.46
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion (2003) 1.41
Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology (2007) 1.40
Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr (2001) 1.30
Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr (2002) 1.29
Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol (2001) 1.26
The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat (2008) 1.11
Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol (2001) 1.09
Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis (1997) 1.03
Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology (2001) 1.03
Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat (2005) 0.99
Viral and host factors in early hepatitis C virus infection. Hepatology (2005) 0.98
Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening. Transfusion (2003) 0.95
High levels of subgenomic HCV plasma RNA in immunosilent infections. Virology (2007) 0.93
Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment. Clin Infect Dis (2005) 0.93
Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect (2006) 0.91
Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion (2004) 0.87
US NAT yield: where are we after 2 years? Transfus Med (2002) 0.85
National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infection. J Clin Gastroenterol (2006) 0.83
Evidence of hepatitis C virus viremia without detectable antibody to hepatitis C virus in a blood donor. Ann Intern Med (2000) 0.83
Failure to diagnose recent hepatitis C virus infections in London injecting drug users. J Med Virol (2004) 0.82
Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Transfusion (2005) 0.81
Prolonged antibody-negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient. Transfusion (2000) 0.78
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med (2004) 5.78
Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76
An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med (2010) 5.32
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation (2013) 3.84
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol (2011) 3.66
Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis (2002) 3.53
High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol (2011) 3.49
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother (2004) 3.48
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS (2002) 3.22
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Emergency department use among the homeless and marginally housed: results from a community-based study. Am J Public Health (2002) 3.21
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health (2003) 3.03
HIV seroprevalence among homeless and marginally housed adults in San Francisco. Am J Public Health (2004) 2.96
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Virus and antibody dynamics in acute west nile virus infection. J Infect Dis (2008) 2.84
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
Convenience, the bane of our existence, and other barriers to donating. Transfusion (2006) 2.69
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health (2005) 2.56
The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion (2009) 2.56
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol (2002) 2.56
Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion (2011) 2.53
A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion (2005) 2.51
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
Biospecimen repositories: are blood donors willing to participate? Transfusion (2010) 2.33
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med (2005) 2.32
The consequences of temporary deferral on future whole blood donation. Transfusion (2007) 2.31
Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion (2008) 2.27
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr (2003) 2.21
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
The detection of acute HIV infection. J Infect Dis (2010) 2.14
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
BRIEF REPORT: the aging of the homeless population: fourteen-year trends in San Francisco. J Gen Intern Med (2006) 2.03
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology (2006) 2.03
The impact of male-to-male sexual experience on risk profiles of blood donors. Transfusion (2005) 2.02
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion (2009) 2.00
Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion (2003) 2.00
A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend (2003) 1.99
Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health (2003) 1.97
Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health (2003) 1.96
The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol (2011) 1.93
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
The whole is greater than the sum of its parts: hemostatic profiles of whole blood variants. J Trauma Acute Care Surg (2014) 1.88
Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion (2010) 1.88
The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med (2005) 1.88
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology (2002) 1.88
Revolving doors: imprisonment among the homeless and marginally housed population. Am J Public Health (2005) 1.86
Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis (2012) 1.86
Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion (2009) 1.85
Donation archives and prospective donor-recipient repositories: indispensable tools for monitoring blood safety. Transfusion (2007) 1.85
Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil. Transfusion (2005) 1.84
Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses (2006) 1.83
Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol (2003) 1.82
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81